PSA adds biological context
PSA can rise for reasons other than cancer. Some significant cancers occur below commonly used PSA thresholds.
SIMONMED LONGEVITY · HEALTHCHECK 2.1
Prostate MRI screening
See beyond
PSA alone.
Non-contrast prostate MRI with OnQ analysis and expert radiologist review adds an imaging perspective to PSA, family history and your personal risk.
BUNDLED ADD-ON RATE$150with your $399 HealthCheck 2.0
WHY IT MATTERS
Earlier insight.
More informed choices.
1 in 8U.S. men will be diagnosed with prostate cancer in their lifetime.
36,320Estimated U.S. prostate cancer deaths in 2026.
These American Cancer Society estimates show why a thoughtful screening conversation matters. A PSA blood test is useful, but neither an elevated PSA nor a reassuring PSA tells the whole story.[1]
MRI adds a map
MRI looks for suspicious areas and helps guide whether targeted biopsy or continued monitoring should be discussed.
Early diagnosis can widen the choices
Localized disease may allow curative surgery or radiation. Selected low-risk cancers can be monitored with active surveillance, avoiding immediate treatment.[6]
2025–2026 RESEARCH
More than twice the detection.
A specific study, a meaningful signal.
The randomized PROSA trial compared an MRI-first pathway with a pathway that used PSA to decide who received MRI. Among 759 randomized men, clinically significant cancer was found in 4.6% versus 1.8%.[2]
This supports looking beyond a PSA threshold alone. It does not mean every individual’s detection rate doubles, and the study did not test OnQ or demonstrate a reduction in prostate cancer deaths.
Clinically significant cancer detection
MRI first4.6%
PSA-gated MRI1.8%
PROSA · randomized screening study
Online 2025 · published in European Urology, 2026
The trade-off: biopsies were also more frequent (10.8% versus 5.2%). PROSA was a single-center study with limited follow-up; greater detection must be balanced against extra procedures and overdiagnosis.[2]
WHY NON-CONTRAST MRI
A simpler exam.
Strong diagnostic evidence.
Biparametric MRI combines anatomical images with diffusion imaging, which examines how water moves through tissue. It usually avoids an IV contrast injection.
In the 2025 PRIME trial, non-contrast MRI detected clinically significant cancer in 29.2% of participants versus 29.6% with contrast-enhanced MRI, meeting the study’s noninferiority criterion. The 490 participants already had suspected prostate cancer; these are not screening yields for healthy men.[3]
THE GOALFind cancers that matter.
Find cancers that matter.
Avoid treating every finding.
“Clinically significant” generally refers to Grade Group 2 or higher cancer in these studies. MRI helps assess concern; tissue diagnosis and clinical context determine what a finding means.
ONQ AT SIMONMED
An additional layer
of quantitative insight.
SimonMed uses OnQ Prostate, FDA-cleared post-processing software built on restriction spectrum imaging (RSI). Its quantitative maps highlight restricted diffusion associated with suspicious tissue, adding information to the radiologist’s interpretation.[4]
Analyze the MRI
OnQ processes specialized diffusion data to create restricted-signal maps and a quantitative score.
Review the whole picture
The radiologist considers the maps with the MRI, PSA information and clinical history. A software score does not diagnose cancer.
Choose the next step
A reassuring result may support monitoring; a suspicious result can lead to urology review and consideration of targeted biopsy.
A 2025 multicenter retrospective study included 1,892 patients and supported RSI as a useful quantitative biomarker. Its strongest performance came from combining information, including expert MRI assessment and PSA density. This is promising complementary evidence, not proof that AI replaces radiologists or biopsy.[5]
YOUR EXAM
Advanced Testing.
Results. Plan.
Before
Share PSA results, family history, previous biopsies and any implants or metal. The team confirms MRI suitability and preparation.
During
Lie still for a focused MRI. The screening protocol is designed without routine IV contrast; your team confirms the final protocol.
After
Receive an expert report and discuss whether routine monitoring, urology evaluation or further testing is appropriate.
GOOD TO KNOW
Your questions,
answered.
Who should consider it?
Discuss it with your clinician based on age, PSA pattern, family history, ancestry and preferences. This offer is not a recommendation that every man needs an MRI.
Is a PSA blood test included in the $150 add-on?
The $150 rate is for the prostate MRI add-on. Bring a recent PSA result; the concierge must confirm whether additional PSA testing is needed and how it is priced.
Does a normal MRI rule out cancer?
No. MRI and PSA can both miss cancer. Ongoing screening or biopsy may still be appropriate when clinical suspicion is high.
GO FURTHER, THOUGHTFULLY
Connect the right tests.
CONCIERGE SIMONMED LONGEVITY SCHEDULING
Make it part
of your conversation.
xxx xxx xxxx
Locations nationwide · Exam availability varies by location.
HealthCheck 2.1 · $150
Bundled with your $399 HealthCheck 2.0. Add-ons require clinical suitability and may need more time or a separate appointment.
Plan your visit ↗THE EVIDENCE BEHIND THE EXPLANATION
Sources & science.
- American Cancer Society. Key statistics for prostate cancer; 2026 estimates.
- PROSA trial. European Urology, 2026; online December 2025. MRI-first versus PSA-based screening.
- PRIME trial. JAMA, 2025. Biparametric versus multiparametric MRI.
- Cortechs.ai. OnQ Prostate product and regulatory information.
- Rojo Domingo et al. Journal of Urology, 2025. RSI as a quantitative prostate cancer biomarker.
- National Cancer Institute. Prostate Cancer Treatment (PDQ), patient version.
Sources reviewed September 19, 2026. Study populations and limitations are described above. Educational information complements individualized medical care.